Drug Type Small molecule drug |
Synonyms VMD 928 |
Target |
Mechanism TrkA antagonists(Nerve growth factor receptor Trk-A antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenoid Cystic Carcinoma | Phase 1 | US | 08 Jun 2018 | |
Adenoid Cystic Carcinoma | Phase 1 | PR | 08 Jun 2018 | |
Advanced Head and Neck Carcinoma | Phase 1 | US | 08 Jun 2018 | |
Advanced Head and Neck Carcinoma | Phase 1 | PR | 08 Jun 2018 | |
Bladder Cancer | Phase 1 | US | 08 Jun 2018 | |
Bladder Cancer | Phase 1 | PR | 08 Jun 2018 | |
Breast Cancer | Phase 1 | US | 08 Jun 2018 | |
Breast Cancer | Phase 1 | PR | 08 Jun 2018 | |
Esophageal Carcinoma | Phase 1 | US | 08 Jun 2018 | |
Esophageal Carcinoma | Phase 1 | PR | 08 Jun 2018 |
NCT03556228 (ASCO2021) Manual | Phase 1 | 20 | xlmvyaswei(hsdykoahhk) = The recommended phase 2 dose (RP2D) is 600 mg twice (1200 mg) per day. zzdqdbhjhr (xequkrpket ) View more | Positive | 20 May 2021 |